Aug 27, 2013|
Dr. Levi Garraway is an oncologist and researcher for Cancer Genome Discovery at the Dana-Farber. Dr. Garraway focuses on personalized medicine, which identifies specific and specialized treatments for individual patients. Dana-Farber is unique in that they have great clinicians and researchers who work side by side in partnership with each other discussing complex issues-solving problems and forming discoveries together.
Listen to some of the highlights from Day 2 of the 12th annual Jimmy Fund Radio-Telethon. Thank you for your support
Mikey and Joe talk with Lisa Scherber, the Director of Dana-Farber/Children's Hospital Cancer Center and VP/GM of WEEI Jeff Brown. Lisa and Jeff worked together to make this year's Jimmy Fund Telethon a rousing success. The final number raised surpassed last years total. Lisa speaks to her interactions with the children and the amazing feeling the entire event brings.
Mikey and Joe talk with Dr. Andrew Place, Pediatric Oncologist and Associate Director of Developmental Therapeutics at Dana-Farber, about the success of the program, and their aspirations to continually improve. Dr. Place talks about the challenges that he and his colleagues face regarding the treatment of adults and children with blood and other types of cancer.
Former Red Sox and Current Baltimore Oriole General Manager Dan Duquette talks with Mikey and Joe about his efforts and contributions to the Jimmy Fund telethon and his experiences during his tenure in Boston.
Automatically Generated Transcript (may not be 100% accurate)
-- continue to ask you the next couple days to donate so that guys like our next guest can get to war get back to work and that's doctor Levi gear away. It was a psychologist and researcher for cancer genome discovery over Dana Farber -- lock up deal. And a Red Sox game I say -- what is what does that mean what what do you do what does that title would you tell me. -- -- Here -- throughout the day. Based on where in the body -- -- but actually that's not what cancer is cancer is a disease of Jean's gone wrong in this cells that are not Kansas also really. To understand -- to treat your right we have to. Understand what went wrong in each patient's tumor and develop drugs to treat. That's -- that's what personalized medicine is so. That's why do everyday is try to figure out how to do that. Better and better and more more cancers so early today wisest thing headed I mean how how exciting are you moving forward let's say there's never been a time in history like this well first of all week that the explosion of technology over the past ten or fifteen years has made it possible to generate this kind of this kind of data. Tuesday early in all of the relevant changes things have gone wrong in genes of tumor so we can get that assessing. Not that hard to get that data. The challenge now is to be interpreted to an interpreter for clinicians and they can understand. What it means and then. More more use new and emerging therapies to match the right drug to the right -- and based on -- Permission Sony -- the personalized medicine dumbed down for an idiot like me so it sounds like instead of taking Nissan. Large phrase shock and and all these different things you try to find that one sort of laser focused approach. And attack it that way is that. Along lines -- what you guys are doing that's basically right no I didn't wanna do it for each patient's tumor so. Three patients login with colon cancer. But one person has a certain kind of colon cancer based on the genes that went wrong another persons are very different kind of colon cancer and you have to treat them very differently so even though it's colon cancer it's not the same. Cancer free education -- the norm so -- we -- based on. For -- get impatient walks in the door what went wrong in their cancer can we give him the right to remain in that way. That's pretty amazing when you think about it where where where you were before and where you are now. This sounds expensive this sounds like something that you need money for I heard a doctor today doctor David -- and save it in his opinion we are an all time low. For research dollars is that the way you see it as well. Well we certainly are in a crisis. In terms of federal funding that we've never been in before then we we haven't really seen meaningful increases and federal funding for cancer research for quite a long time so it's causing us to have to do. More with less and as you say. To do to really built about a different sources like very generous people to fund would really is. Potentially transformative time in -- received so you're absolutely right overdue farm we have to commit to a clinicians and researchers -- actually working together. Is that unique. You see a -- elsewhere. Plowed -- one of those special things about being a foreigner is a special place is that the mission is. It's both. Outstanding patient care and bringing the best science to improve patient care so we have. People from basic sciences to clinical researchers to oncologists. Then more more and they are coming together to sort of see how can we make the transfer on the basic discoveries to the clinic and we are. I would say that there are. Not to new places in the world -- that kind of synergy. That -- -- to be able to bring that. That collective knowledge forward for patients like I'm just killing what were you working on today before he came over here what was is it a project is sitting -- -- -- what do always your today life. -- a month would typically what I do any given day is you know I was we have several projects that are relevant to particular cancers melanoma prostate cancer breast cancer colon cancer and so I meet with us. One of the people in the group sometimes it's good doctors and hundreds of basic scientist to figure out OK where are we didn't do this idea work we had this idea of maybe there's a new kind of drugs don't work against these kind of cancer did it work. And if not why not if so what do we do next so it's really. Take in the information that's coming in for me -- that we try. I'm thinking about it understanding what can we do better but all left our our lab is it if we do a lot of basic scientists always geared towards. How could make patients with particular types of cancer do better how can this make its way into the clinic and hopefully help the patient. You can see yourself impatient and later when it comes to these things orders that you leave every day saying you know today was enough I want more or. It's going to come live every day it's gonna happen when -- -- find cures. You know it's a shame I think on the one hand you have to be patient and and allow believe the projects and then -- research unfold on the other hand. You can't beat you and I I would say no I'm not really all that patient we need to be pushing this farther there's so much more than we can do for patients. It is just. Perez you say it's a matter of resources and maligning them and just making sure that we can bring as much of this knowledge in the clinic as possible. -- Isn't as great as the strides have been over the past years we -- not where we need to be and -- be the first person to admit that but hey tremendously good morning us and get us there. Is this a teammate type mentality where the people you're working alongside -- working towards one major -- or is there -- competition. Amongst each other try to get their first. You know I think Dan Farber this this turned that we use called -- science I think that the research that. We do it if it epitomizes -- signs because there's so many different members of so many different areas of medicine and research that are needed to get this done now having said that. There are other places around the country -- world that are trying to also. Make advances so there is. Friendly competition in the field I would say that that is -- generally it's friendly because we're all about the same thing but you know a little competition is good but I think it Dana Farber I think teams sciences relive the best way to describe what we do. So the key is more money and we're gonna get people to donate more money you have more money to get back to work and work on his process doctor thank you so much for it. Helping -- sell the information today thank you are very grateful -- doctor Levi caraway oncologist and researcher for the cancer genome discovery there hi Dana Farber joining us as we can.
Dr. Tony Schena joined the show to give insight into what lies ahead for Rob Gronkowski. He said a tough road is in front of the Patriots tight end.
We discuss the improbable win over the Browns and the loss of Rob Gronkowski with Patriots Head Coach Bill Belichick on Patriots Monday.
Ninkovich sits in with Mut and Merloni to look back at yesterday’s comeback win against the Browns. Rob also explains the range of emotions the team experienced after Rob Gronkowski suffered a potentially season ending injury.
Eagle checks in to give Grande and Max a perspective on the Brooklyn Nets after they acquired Paul Pierce and Kevin Garnett via trade earlier this summer. He breaks down what he thinks the future holds for the Nets after completing this blockbuster deal.
Sean Grande and Cedric Maxwell take some time and look back at the history between the Celtics and the Lakers, specifically the legendary rivalry between Magic and Bird. Legendary broadcaster, Ian Eagle, checks in to give the Brooklyn perspective as KG and Paul Pierce settle into their new home. Sean and Max also reveal the behind the scenes details surrounding Max’s famous “I got the ball” moment.
In the first hour of this edition of the Celtics Summer Cooler, Grande and Max analyze the trade that sent Fab Melo out of Boston. Also in this hour, Max sets the story straight about his history with Larry Bird.
It's a baseball round table from the winter meetings in Orlando, Rob Bradford talks with Ian Browne, Scott Lauber, Tim Britton, and Jason Mastrodonato.
Buster joins Mut and Merloni live at the Winter Meetings in Orlando. Buster explains that the market for Stephen Drew has cooled off considerably and executives around the league believe he will return to Boston.
Hazen talks with Mut and Merloni about the on-going offseason process. Mike explains how the Red Sox dove in to free agency immediately after the team’s World Series win. He also explains how the team creates opportunities for young players that are ready to make the jump to the Major League level.
Shawn Thornton joined the show and discussed the teams long layoff leading into their game tomorrow night in Montreal. He told the guys that he anticipates fighting being a part of hockey for years to come.
Lucic joins Danny Picard to talk some hockey after the team’s overtime win against the Carolina Hurricanes. Danny asks Lucic about David Krejci’s game winner yesterday and hockey outsiders that are trying to change the game.
Shawn Thornton joined the show fresh off his big night at MSG and talked about his recent goal scoring prowess. Shawn said that no matter who his line mates are he is always going to be a fourth liner.
The top stories of the day as recounted by Kirk Minihane. Today the guys went over a list of the most annoying people to see on your flight.
The guys opened the show discussing the great reception Doc Rivers got last night at The Garden. They said it was not surprising and well deserved.
Boston College running back Andre Williams joined the show and discussed his record setting season. He said that he will work on his acceptance speech on the flight down to New York.
Jackie MacMullan joins the show to discuss the return of Doc Rivers to Boston and what really happened during the offseason that led to Doc's departure.
Brick joins Mut and Merloni to discuss Shawn Thornton's on ice actions last week against the Penguins and what type of suspension he may be facing.
Mut and Merloni react to Doc Rivers' emotional return to Boston and they discuss the way he left the Celtics.
We debate the hit, and what Shawn Thornton deserves to get and will get for a suspension from the NHL when he faces his discipline hearing on Friday for his K/O hit of the Penguins Brooks Orpik.
We check in with Jack Edwards of NESN and focus on the Bruins, and more specifically Sean Thornton's upcoming discipline hearing for his cheap-shot hit on Brooks Orpik of the Penguins.
We focus on multi-sport athletes in today's four topics at 4PM.
Ryder talks with WEEI.com's Chris Price about the Patriots upcoming game with the Cleveland Browns, and Stevan Ridley's status on the team.
Alex joins the show and gives his thoughts on the Jacoby Ellsbury deal, and what prospects the Red Sox have to fill the hole left in the lineup, or trade pieces to get a player who can fill the void.
John talks to Rob and gets his thoughts on the Yankees signing Jacoby Ellsbury, the Red Sox signing AJ Pierzynski, and Jarrod Saltalamacchia signing with Miami.
No Jenny Dell today, but Mikey's back and we're answering questions bitches!
We answer what you ask... and by we mean Salk, Holley and special guest Jenny Dell of NESN!
Answering questions, its what we do.
Kurkjian joins Mut and Merloni at the Winter Meetings to talk about the Red Sox plans on the market. Tim believes the Red Sox are not satisfied with their situation in center and are looking to add a veteran outfielder to the mix.More from this show
Buster joins Mut and Merloni live at the Winter Meetings in Orlando. Buster explains that the market for Stephen Drew has cooled off considerably and executives around the league believe he will return to Boston.More from this show
Millar sits in with the guys on location in Orlando at MLB's Winter Meetings. He covers all the bases with Mut and Lou on all the Red Sox free agent possibilities and potential trades.More from this show
We discuss the comers and goers for the Red Sox and the rest of MLB with former GM Steve Phillips, now of MLB Radio on Sirius XM.More from this show
We discuss the improbable win over the Browns and the loss of Rob Gronkowski with Patriots Head Coach Bill Belichick on Patriots Monday.More from this show